Seres Therapeutics Inc MCRB.OQ MCRB.O is expected to show no change in quarterly revenue when it reports results on August 6 for the period ending June 30 2025
LSEG's mean analyst estimate for Seres Therapeutics Inc is for a loss of $2.49 per share.
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy," 2 "hold" and no "sell" or "strong sell."
The mean earnings estimate of analysts was unchanged in the last three months.
Wall Street's median 12-month price target for Seres Therapeutics Inc is $14.00, about 0.1% above its last closing price of $13.99
Previous quarterly performance (using preferred earnings measure in US dollars).
QUARTER ENDING | STARMINESMARTESTIMATE® | LSEG IBES ESTIMATE | ACTUAL | BEAT, MET, MISSED | SURPRISE % |
Mar. 31 2025 | -1.25 | -0.54 | -2.96 | Missed | -448.1 |
Dec. 31 2025 | -3.75 | -3.94 | -2.00 | Beat | 49.2 |
Sep. 30 2024 | -4.88 | -4.91 | -7.60 | Missed | -54.8 |
Jun. 30 2024 | -5.46 | -5.48 | -4.40 | Beat | 19.7 |
Mar. 31 2024 | -6.95 | -6.82 | -5.40 | Beat | 20.8 |
Dec. 31 2023 | -7.95 | -9.94 | -6.40 | Beat | 35.6 |
Sep. 30 2023 | -9.87 | -10.03 | -7.40 | Beat | 26.2 |
Jun. 30 2023 | 10.58 | 10.68 | 7.20 | Missed | -32.6 |
This summary was machine generated August 4 at 13:43 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)